CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Exercise physiologyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug1395 Lung Function tests Wiki 1.00
drug1640 None - NA Wiki 1.00
drug2084 Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening Wiki 1.00
drug884 Exercise capacity Wiki 1.00
drug1040 Health-related quality of life Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D004932 Esophageal and Gastric Varices NIH 1.00
D003108 Colonic Diseases NIH 1.00
D005764 Gastroesophageal Reflux NIH 0.58

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002040 Esophageal varix HPO 1.00
HP:0002020 Gastroesophageal reflux HPO 0.58

There is one clinical trial.

Clinical Trials


1 Short and Long Term Assessment of Lung Function, Exercise Capacity and Health-Related Quality of Life in Survivors of Severe COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe disease requiring hospitalization and oxygen support in around14% of the cases and 5% require admission in intensive care unit. The medium and long-term impact in survivors of severe COVID-19 on lung function, exercise capacity and health-related quality of life remains to be determined.

NCT04410107 COVID-19 SARS-CoV-2 Infection Diagnostic Test: Lung Function tests Diagnostic Test: Exercise capacity Diagnostic Test: Exercise physiology Diagnostic Test: Health-related quality of life Diagnostic Test: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening

Primary Outcomes

Description: ratio obtained from measured values during spirometry

Measure: Forced expiratory volume in the first second/forced vital capacity

Time: 6 months

Description: obtained from plethysmography (% of predicted)

Measure: Total lung capacity

Time: 6 months

Description: obtained from single-breathe maneuver (% of predicted)

Measure: Lung diffusion capacity for carbon monoxide

Time: 6 months

Description: distance walked during the test (m)

Measure: 6-minute walk test distance

Time: 6 months

Description: scores range between 0 and 100 with higher scores indicating a better HRQoL

Measure: Short-form 36 questionnaire (SF-36)

Time: 6 months

Secondary Outcomes

Description: ratio obtained from measured values during spirometry

Measure: Forced expiratory volume in the first second/forced vital capacity

Time: 12 and 24 months

Description: % of predicted

Measure: Forced vital capacity

Time: 6, 12 and 24 months

Description: ratio obtained from measured values during plethysmography

Measure: Residual volume/total lung capacity

Time: 6, 12 and 24 months

Description: ratio obtained from measured values during plethysmography

Measure: Inspiratory capacity/total lung capacity

Time: 6, 12 and 24 months

Description: obtained from body plethysmography

Measure: Airway resistance (Raw)

Time: 6, 12 and 24 months

Description: obtained from single-breathe maneuver (% of predicted)

Measure: Lung diffusion capacity for carbon monoxide

Time: 12 and 24 months

Description: obtained from Impulse oscillometry

Measure: Resistance at 20Hz and 5Hz (R5-R20)

Time: 6, 12 and 24 months

Description: obtained from Impulse oscillometry

Measure: Reactance at 5Hz (X5)

Time: 6, 12 and 24 months

Description: obtained from Impulse oscillometry

Measure: Resonant frequency (Fres)

Time: 6, 12 and 24 months

Description: obtained from Impulse oscillometry

Measure: Reactance area (AХ)

Time: 6, 12 and 24 months

Description: distance walked during the test (m)

Measure: 6-minute walk test distance

Time: 12 and 24 months

Description: before 6-minute walk test

Measure: Pulse oximetry (SpO2) at rest

Time: 6, 12 and 24 months

Description: at the end of 6-minute walk test

Measure: Pulse oximetry (SpO2) during exercise

Time: 6, 12 and 24 months

Description: descriptive/qualitative questionnaire

Measure: Respiratory symptoms adapted from American Thoracic Society Questionnaire

Time: 6, 12 and 24 months

Description: scores range between 0 and 100 with higher scores indicating a better HRQoL

Measure: Short-form 36 questionnaire (SF-36)

Time: 12 and 24 months

Description: from incremental Cardiopulmonary exercise test (% of predicted)

Measure: Oxygen uptake at peak exercise

Time: 6, 12 and 24 months

Description: from incremental Cardiopulmonary exercise test (L/L)

Measure: Minute-ventilation/carbon dioxide output during exercise

Time: 6, 12 and 24 months

Description: from incremental Cardiopulmonary exercise test (measured with 10-point categorical Borg scale)

Measure: Dyspnea during exercise

Time: 6, 12 and 24 months

Description: from incremental Cardiopulmonary exercise test (L and % of predicted)

Measure: Inspiratory capacity during exercise

Time: 6, 12 and 24 months

Description: total score ranges from 0 to 63; higher score indicating higher anxiety

Measure: Beck Anxiety Inventory (BAI)

Time: 6, 12 and 24 months

Description: total scores ranges from 0 to 63; higher score is worse

Measure: Beck Depression Inventory (BDI)

Time: 6, 12 and 24 months

Description: 17-item, 5 likert-scale each item; higher score indicating more symptoms

Measure: Post-traumatic stress symptoms questionnaire

Time: 6, 12 and 24 months


No related HPO nodes (Using clinical trials)